Apr 08, 2020
Alopecia Industry Growth Opportunities, 2020-2027 - Increasing Prevalence of Diseases Across the Globe, Technological Progression, Growth in Per-Capita Expenditures Toward Healthcare
Mar 17, 2020
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
Dec 16, 2019
Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
Sep 13, 2019
Novartis' Cosentyx and Pfizer's Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights
Mar 15, 2019
Information Update - Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR)
Feb 25, 2019
FDA responds to safety signal reported in required postmarketing trial for Xeljanz
Jan 16, 2019
Recent Data Collected by Spherix Global Insights Highlights Key US vs. EU Differences Between Perceptions and Adoption of Eli Lilly's Olumiant and Pfizer's Xeljanz for the Treatment of Rheumatoid Arthritis
Oct 09, 2018
Health Canada Approves New Indications for XELJANZ(TM) in Ulcerative Colitis (UC) & Psoriatic Arthritis (PsA)
Oct 08, 2018
More Rheumatologists are Using Pfizer's Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly's Taltz in the Previous Quarter
Aug 20, 2018
US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor
Jul 17, 2018
Rheumatologist User Base for Eli Lilly's Taltz in Psoriatic Arthritis (PsA) Boasts Strong Growth in Q2, While Use of Pfizer's Xeljanz Has Remained Flat Over the Past Quarter
Jul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis
May 30, 2018
FDA approves new treatment for moderately to severely active ulcerative colitis
May 30, 2018
TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer's Xeljanz and Eli Lilly's Taltz Claim Their Share of the Switching Population
May 10, 2018
Warning to Eli Lilly's Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat
Apr 25, 2018
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Apr 10, 2018
Pfizer's Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly's Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights
Jan 10, 2018
JAK Inhibitors Expected to Introduce Fierce Competition to Treatment Paradigms Across a Wide Range of Autoimmune Indications, Including Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, and Lupus
Dec 04, 2017
Eli Lilly's Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis' Cosentyx
Nov 21, 2017
Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech's RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US